Loading...
Market
Number of new drug candidates from Xaira by 2026
5
Resolution / Starting Odds
0-1 new candidates • 25%
2-3 new candidates • 25%
4-5 new candidates • 25%
More than 5 new candidates • 25%
Company R&D updates, press releases, and healthcare publications
Story
Xaira, Led by CEO Marc Tessier-Lavigne, Raises $1B for RFdiffusion Tech
Apr 25, 2024, 12:25 AM
Xaira, a new biotechnology company, has successfully raised over $1 billion in committed capital, marking one of the largest funding rounds in biotech history. The company, led by CEO Marc Tessier-Lavigne, is set to focus on next-generation technology in biopharma, leveraging AI and RFdiffusion from David Baker's lab. The funding round saw participation from major venture capital firms including Arch, Foresite, F-Prime, NEA, Sequoia, Lux, Lightspeed, and Two Sigma. This significant financial backing underscores the growing interest and investment in tech-driven biopharma solutions.
View original story
Similar markets
No competitive drugs launched • 25%
1-2 competitive drugs launched • 25%
3-5 competitive drugs launched • 25%
More than 5 competitive drugs launched • 25%
0-5 • 20%
6-10 • 20%
11-15 • 20%
16-20 • 20%
More than 20 • 20%
1-2 acquisitions • 33%
3-5 acquisitions • 33%
More than 5 acquisitions • 34%
Less than 5 • 25%
5 to 9 • 25%
10 to 14 • 25%
15 or more • 25%
None • 25%
1-2 • 25%
3-5 • 25%
More than 5 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16 or more countries • 25%
0-5 partnerships • 25%
6-10 partnerships • 25%
11-15 partnerships • 25%
More than 15 partnerships • 25%
None • 20%
1-2 • 20%
3-4 • 20%
5-6 • 20%
7 or more • 20%
0-100 • 25%
101-500 • 25%
501-1000 • 25%
More than 1000 • 25%
0-5 initiatives • 25%
6-10 initiatives • 25%
11-15 initiatives • 25%
More than 15 initiatives • 25%
Less than 10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
More than 30 countries • 25%